BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Du JJ, Su Z, Yu H, Qin S, Wang D. From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy. Front Chem 2022;10:1107600. [PMID: 36733612 DOI: 10.3389/fchem.2022.1107600] [Reference Citation Analysis]
2 Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Current progress in the development of prophylactic and therapeutic vaccines. Sci China Life Sci 2022;:1-32. [PMID: 36469218 DOI: 10.1007/s11427-022-2230-4] [Reference Citation Analysis]
3 Abd-Aziz N, Poh CL. Development of Peptide-Based Vaccines for Cancer. J Oncol 2022;2022:9749363. [PMID: 35342400 DOI: 10.1155/2022/9749363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
5 Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Antitumor Peptide-Based Vaccine in the Limelight. Vaccines (Basel) 2022;10:70. [PMID: 35062731 DOI: 10.3390/vaccines10010070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mukhin VE, Konstantinova YS, Gimadiev RR, Mazurchik NV. Horizons of development of immunotherapy for malignant liver tumors. jour 2021. [DOI: 10.31146/1682-8658-ecg-191-7-81-89] [Reference Citation Analysis]
8 Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif 2021;54:e13025. [PMID: 33754407 DOI: 10.1111/cpr.13025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
9 Hsu YC, Cheng JC. Perspectives of Radiotherapy in Immuno-oncology Era. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_23] [Reference Citation Analysis]
10 Wang J, Li Z, Wang Z, Yu Y, Li D, Li B, Ding J. Nanomaterials for Combinational Radio–Immuno Oncotherapy. Adv Funct Mater 2020;30:1910676. [DOI: 10.1002/adfm.201910676] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
11 Wang M, Tong Y, Luo Q, Hu S. Study of ATP borate ester effects on cell sensitization to radiation emitted by a nuclear reactor. NUCL SCI TECH 2020;31. [DOI: 10.1007/s41365-019-0713-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology 2019;8:e1638212. [PMID: 31646087 DOI: 10.1080/2162402X.2019.1638212] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 20.3] [Reference Citation Analysis]
13 Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol 2018;9:3176. [PMID: 30719026 DOI: 10.3389/fimmu.2018.03176] [Cited by in Crossref: 130] [Cited by in F6Publishing: 145] [Article Influence: 32.5] [Reference Citation Analysis]
14 Galati D, Zanotta S. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy 2018;20:1309-23. [PMID: 30360963 DOI: 10.1016/j.jcyt.2018.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
15 Sun L, Hao Y, Wang Z, Zeng Y. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines. Viruses 2018;10:E145. [PMID: 29570629 DOI: 10.3390/v10040145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]